Segui
David Cipolla
David Cipolla
Insmed
Email verificata su insmed.com
Titolo
Citata da
Citata da
Anno
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
DJ Serisier, D Bilton, A De Soyza, PJ Thompson, J Kolbe, HW Greville, ...
Thorax 68 (9), 812-817, 2013
2982013
Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system
P Chattopadhyay, BY Shekunov, D Yim, D Cipolla, B Boyd, S Farr
Advanced drug delivery reviews 59 (6), 444-453, 2007
2972007
Development of liposomal ciprofloxacin to treat lung infections
D Cipolla, J Blanchard, I Gonda
Pharmaceutics 8 (1), 6, 2016
2102016
Liposomal formulations for inhalation
D Cipolla, I Gonda, HK Chan
Therapeutic delivery 4 (8), 1047-1072, 2013
1912013
Assessment of aerosol delivery systems for recombinant human deoxyribonuclease
DC Cipolla, AR Clark, HK Chan, I Gonda, SJ Shire
STP Pharma Sciences 4 (1), 50-62, 1994
1481994
Physical stability of dry powder inhaler formulations
N Shetty, D Cipolla, H Park, QT Zhou
Expert opinion on drug delivery 17 (1), 77-96, 2020
1462020
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans
D Cipolla, B Shekunov, J Blanchard, A Hickey
Advanced drug delivery reviews 75, 53-80, 2014
1372014
Drug nanocrystallisation within liposomes
T Li, D Cipolla, T Rades, BJ Boyd
Journal of Controlled Release 288, 96-110, 2018
1352018
Pulmonary formulations: what remains to be done?
JG Weers, J Bell, HK Chan, D Cipolla, C Dunbar, AJ Hickey, IJ Smith
Journal of Aerosol Medicine and Pulmonary Drug Delivery 23 (S2), S-5-S-23, 2010
1312010
Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers
D Cipolla, I Gonda, SJ Shire
Pharmaceutical research 11, 491-498, 1994
1021994
Inhaled medicines: past, present, and future
S Anderson, P Atkins, P Bäckman, D Cipolla, A Clark, E Daviskas, B Disse, ...
Pharmacological Reviews 74 (1), 48-118, 2022
952022
Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia
HX Ong, D Traini, D Cipolla, I Gonda, M Bebawy, H Agus, PM Young
Pharmaceutical research 29, 3335-3346, 2012
932012
Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation
D Cipolla, H Wu, S Eastman, T Redelmeier, I Gonda, HK Chan
Journal of pharmaceutical sciences 103 (1), 314-327, 2014
892014
Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles
R Rubsamen, I Gonda, S Farr, D Cipolla
US Patent 5,829,435, 1998
781998
Modifying the release properties of liposomes toward personalized medicine
D Cipolla, H Wu, I Gonda, S Eastman, T Redelmeier, HK Chan
Journal of pharmaceutical sciences 103 (6), 1851-1862, 2014
762014
Dual action, inhaled formulations providing both an immediate and sustained release profile
DC Cipolla, J Blanchard
US Patent 8,071,127, 2011
762011
Inhaled liposomal ciprofloxacin: once a day management of respiratory infections
P Bruinenberg, JD Blanchard, DC Cipolla, F Dayton, S Mudumba, ...
Respiratory drug delivery 1, 73-82, 2010
752010
Formulation technology to repurpose drugs for inhalation delivery
DC Cipolla, I Gonda
Drug Discovery Today: Therapeutic Strategies 8 (3-4), 123-130, 2011
742011
Minimizing variability of cascade impaction measurements in inhalers and nebulizers
M Bonam, D Christopher, D Cipolla, B Donovan, D Goodwin, S Holmes, ...
Aaps Pharmscitech 9, 404-413, 2008
742008
In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation
HX Ong, F Benaouda, D Traini, D Cipolla, I Gonda, M Bebawy, B Forbes, ...
European Journal of Pharmaceutics and Biopharmaceutics 86 (1), 83-89, 2014
642014
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20